MyFinsight
Home
Blog
About
Contact
Download
Download image
Total comprehensive
loss
-$308,066K
(-37.05%↓ Y/Y)
Unrealized gain (loss) on
marketable securities
$3,285K
(452.09%↑ Y/Y)
Interest and other income
$38,418K
(1.03%↑ Y/Y)
Net loss
-$311,351K
(-39.08%↓ Y/Y)
Total other income
$38,048K
(0.72%↑ Y/Y)
Interest and other
expense
$370K
(48.59%↑ Y/Y)
Loss from operations
-$349,399K
(-33.54%↓ Y/Y)
Collaboration revenue
$39,211K
(-16.70%↓ Y/Y)
Total operating
expenses
$388,610K
(25.88%↑ Y/Y)
Research and development
$316,568K
(31.77%↑ Y/Y)
General and
administrative
$68,187K
(7.32%↑ Y/Y)
Impairment of long-lived
assets
$3,855K
(-21.73%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Kymera Therapeutics, Inc. (KYMR)
Kymera Therapeutics, Inc. (KYMR)